You are here:
Venclyxto
Treatment of Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation in combination with obinutuzumab and ibrutinib.
No judgement
45,300,000.00
Clinical trials
Venetoclax
Oncology and Hematology
Indication extension
Leukemia
Abbvie
Oral
Tablet
Intermural (MSZ)
Bcl-2 remmer
Centralised (EMA)
Normal trajectory
2020
Yes
Venetoclax is in de sluis geplaatst.
Fludarabine, Cyclophosphamide, Rituximab.
< 600
Market share is generally not included unless otherwise stated.
Geschat wordt dat er jaarlijks zo'n 600 patiënten in de 1e lijn behandeld worden. Deze patiënten komen dan in aanmerking voor venetoclax (maximum).
73,000.00 - 78,000.00
Medicijnkosten.nl; SmPC venetoclax
Op basis van SmPC en AIP zijn de kosten €73.000,00-€78.000,00 per jaar. Venetoclax is in de sluis geplaatst om te komen tot een financieel arrangement.
This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.
No
Mantle-cell lymphoma; Multiple myeloma (lopende fase III studies)
AdisInsight
There is currently no futher information available.
Understanding of expected market entry of innovative medicines